Effects of rapamycin and cotylenin A on breast cancer cells
Author Information
Author(s): Kasukabe Takashi, Okabe-Kado Junko, Kato Nobuo, Sassa Takeshi, Honma Yoshio
Primary Institution: Saitama Cancer Center
Hypothesis
Can the combination of rapamycin and cotylenin A enhance the growth-inhibitory effects on MCF-7 breast cancer cells?
Conclusion
The combination of rapamycin and cotylenin A significantly inhibits the growth of MCF-7 breast cancer cells both in vitro and in vivo.
Supporting Evidence
- The combination treatment induced growth arrest at the G1 phase rather than apoptosis.
- Gene expression analysis showed significant modulation of several genes in treated MCF-7 cells.
- Combined treatment significantly inhibited tumor growth in xenograft models.
Takeaway
Using two medicines together can help stop breast cancer cells from growing better than using just one medicine alone.
Methodology
The study used MTT assays, trypan blue dye exclusion tests, and cDNA microarray analysis to evaluate the effects of treatments on MCF-7 cells and xenografts.
Limitations
The study primarily focused on one breast cancer cell line and may not generalize to all breast cancer types.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website